Press releases
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
- Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
More ▼
Key statistics
On Wednesday, Organon & Co (1OGN:MIL) closed at 16.03, -11.90% below its 52-week high of 18.19, set on Feb 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.03 |
---|---|
High | 16.03 |
Low | 16.03 |
Bid | -- |
Offer | -- |
Previous close | 17.26 |
Average volume | 0.00 |
---|---|
Shares outstanding | 255.64m |
Free float | 255.27m |
P/E (TTM) | 4.65 |
Market cap | 4.74bn USD |
EPS (TTM) | 3.99 USD |
Annual div (ADY) | 1.04 EUR |
---|---|
Annual div yield (ADY) | 5.98% |
Div ex-date | Feb 23 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Mar 06 2024 10:59 GMT.
More ▼